Skip to main content
Erschienen in: Journal of Neurology 7/2019

15.04.2019 | Original Communication

Motor, cognitive and behavioral differences in MDS PSP phenotypes

verfasst von: Marina Picillo, Sofia Cuoco, Maria Francesca Tepedino, Arianna Cappiello, Giampiero Volpe, Roberto Erro, Gabriella Santangelo, Maria Teresa Pellecchia, Paolo Barone, The PSP Salerno study group

Erschienen in: Journal of Neurology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Movement Disorder Society (MDS) new diagnostic criteria for Progressive Supranuclear palsy (PSP) identifying different disease phenotypes were recently released. The aim of the present study is to report on the cognitive and behavioral features of the different phenotypes diagnosed according to the MDS criteria.

Methods

Forty-nine PSP patients underwent an extensive battery of clinical assessments. Differences between PSP subtypes were computed with χ2 or ANOVA tests. Using the z scores, subjects were classified as having normal cognition, mild cognitive impairment, single or multiple domain, and dementia. A logistic regression model was implemented to investigate the major determinants of PSP non-Richardson’s syndrome phenotype.

Results

Half of the cohort presented Richardson’s syndrome (46.9%), followed by PSP with parkinsonism and corticobasal syndrome (22.4% and 14.2%, respectively). Richardson’s syndrome and PSP with corticobasal syndrome presented a similar burden of disease. The only cognitive testing differentiating the phenotypes were semantic fluency and ideomotor apraxia. The majority of our cohort was either affected by dementia or presented normal cognition. Richardson’s syndrome presented the highest rate of dementia. The only marker of PSP non-Richardson’s syndrome phenotype was better performance in visuo-spatial testing, implying worse visuo-spatial abilities in PSP Richardson’s syndrome.

Conclusion

Available clinical assessments hardly capture differences between PSP phenotypes. The cognitive testing differentiating the PSP phenotypes were semantic fluency and ideomotor apraxia. In PSP, mild cognitive impairment likely represents an intermediate step from normal cognition to dementia. The only marker of PSP non-Richardson’s syndrome phenotype was better performance in visuo-spatial testing.
Literatur
1.
Zurück zum Zitat Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16(7):552–563CrossRefPubMedPubMedCentral Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16(7):552–563CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Litvan I, Agid Y, Calne D, Campbell B et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-PSP international workshop. Neurology 47(1):1–9CrossRefPubMed Litvan I, Agid Y, Calne D, Campbell B et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-PSP international workshop. Neurology 47(1):1–9CrossRefPubMed
3.
Zurück zum Zitat Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 32(6):853–864CrossRefPubMedPubMedCentral Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 32(6):853–864CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Santangelo G, Cuoco S, Pellecchia MT, Erro R, Barone P, Picillo M (2018) Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. J Neurol 265(11):2602–2613CrossRefPubMed Santangelo G, Cuoco S, Pellecchia MT, Erro R, Barone P, Picillo M (2018) Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. J Neurol 265(11):2602–2613CrossRefPubMed
5.
Zurück zum Zitat Gerstnecker A (2017) The neuropsychology (broadly conceived) of multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Arch Clin Neuropsychol 32(7):861–875CrossRef Gerstnecker A (2017) The neuropsychology (broadly conceived) of multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Arch Clin Neuropsychol 32(7):861–875CrossRef
6.
Zurück zum Zitat Pilotto A, Gazzina S, Benussi A et al (2017) Mild cognitive impairment and progression to dementia in progressive supranuclear palsy. Neurodegener Dis 17(6):286–291CrossRefPubMed Pilotto A, Gazzina S, Benussi A et al (2017) Mild cognitive impairment and progression to dementia in progressive supranuclear palsy. Neurodegener Dis 17(6):286–291CrossRefPubMed
7.
Zurück zum Zitat Gerstenecker A, Mast B, Duff K, Ferman TJ (2013) Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. Arch Clin Neuropsychol 28(2):104–113CrossRefPubMed Gerstenecker A, Mast B, Duff K, Ferman TJ (2013) Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. Arch Clin Neuropsychol 28(2):104–113CrossRefPubMed
8.
Zurück zum Zitat Millar D, Griffiths P, Zermansky AJ, Burn DJ (2016) Characterizing behavioural and cognitive dysexecutive changes in progressive supranuclear palsy. Mov Disord 21(2):199–207CrossRef Millar D, Griffiths P, Zermansky AJ, Burn DJ (2016) Characterizing behavioural and cognitive dysexecutive changes in progressive supranuclear palsy. Mov Disord 21(2):199–207CrossRef
9.
Zurück zum Zitat Brown RG, Lacomblez L, Landwehrmeyer BG et al (2010) Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 133(8):2382–2393CrossRefPubMed Brown RG, Lacomblez L, Landwehrmeyer BG et al (2010) Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 133(8):2382–2393CrossRefPubMed
10.
Zurück zum Zitat Cordato N, Pantelis C, Halliday GM et al (2002) Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 125(4):789–800CrossRefPubMed Cordato N, Pantelis C, Halliday GM et al (2002) Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 125(4):789–800CrossRefPubMed
11.
Zurück zum Zitat Pellicano C, Assogna F, Cellupica N et al (2017) Neuropsychiatric and cognitive profile of early Richardson’s syndrome, progressive supranuclear palsy-parkinsonism and Parkinson’s disease. Parkinsonism Relat Disord 45:50–56CrossRefPubMed Pellicano C, Assogna F, Cellupica N et al (2017) Neuropsychiatric and cognitive profile of early Richardson’s syndrome, progressive supranuclear palsy-parkinsonism and Parkinson’s disease. Parkinsonism Relat Disord 45:50–56CrossRefPubMed
12.
Zurück zum Zitat Picillo M, Erro R, Cuoco S, Tepedino MF, Manara R, Pellecchia MT, Barone P (2017) MDS PSP criteria in real-life clinical setting: motor and cognitive characterization of subtypes. Mov Disord 33(8):1361–1365CrossRef Picillo M, Erro R, Cuoco S, Tepedino MF, Manara R, Pellecchia MT, Barone P (2017) MDS PSP criteria in real-life clinical setting: motor and cognitive characterization of subtypes. Mov Disord 33(8):1361–1365CrossRef
13.
Zurück zum Zitat Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt 6):1552–1565CrossRefPubMed Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt 6):1552–1565CrossRefPubMed
14.
Zurück zum Zitat Payan CA, Viallet F, Landwehrmeyer BG et al (2011) NNIPPS Study Group. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS–Parkinson Plus Scale. PLoS One 6(8):e22293CrossRefPubMedPubMedCentral Payan CA, Viallet F, Landwehrmeyer BG et al (2011) NNIPPS Study Group. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS–Parkinson Plus Scale. PLoS One 6(8):e22293CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat The EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef The EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef
16.
Zurück zum Zitat Kjaergaard M, Arfwedson W, Waterloo K, Jorde R (2014) A study of the psychometric properties of the Beck Depression Inventory-II, the Montgomery and Åsberg Depression Rating Scale, and the Hospital Anxiety and Depression Scale in a sample from a healthy population. Scand J Psychol 55(1):83–89CrossRefPubMed Kjaergaard M, Arfwedson W, Waterloo K, Jorde R (2014) A study of the psychometric properties of the Beck Depression Inventory-II, the Montgomery and Åsberg Depression Rating Scale, and the Hospital Anxiety and Depression Scale in a sample from a healthy population. Scand J Psychol 55(1):83–89CrossRefPubMed
17.
Zurück zum Zitat Santangelo G, Barone P, Cuoco S, Raimo S, Pezzella D, Picillo M, Vitale C (2014) Apathy in untreated, de novo patients with Parkinson‘s disease: validation study of apathy evaluation scale. J Neurol 261:2319–2328CrossRefPubMed Santangelo G, Barone P, Cuoco S, Raimo S, Pezzella D, Picillo M, Vitale C (2014) Apathy in untreated, de novo patients with Parkinson‘s disease: validation study of apathy evaluation scale. J Neurol 261:2319–2328CrossRefPubMed
18.
Zurück zum Zitat Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356CrossRefPubMedPubMedCentral Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Höglinger GU (2018) Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders? No. Mov Disord Clin Pract 5(2):141–144CrossRefPubMedPubMedCentral Höglinger GU (2018) Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders? No. Mov Disord Clin Pract 5(2):141–144CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Vita MG, Marra C, Spinelli P et al (2014) Typicality of words produced on a semantic fluency task in amnesic mild cognitive impairment: linguistic analysis and risk of conversion to dementia. J Alzheimers Dis 42(4):1171–1178CrossRefPubMed Vita MG, Marra C, Spinelli P et al (2014) Typicality of words produced on a semantic fluency task in amnesic mild cognitive impairment: linguistic analysis and risk of conversion to dementia. J Alzheimers Dis 42(4):1171–1178CrossRefPubMed
22.
Zurück zum Zitat Owen AM, James M, Leigh PN et al (1992) Fronto-striatal cognitive deficits at different stages of Parkinson’s disease. Brain 16:1727–1751CrossRef Owen AM, James M, Leigh PN et al (1992) Fronto-striatal cognitive deficits at different stages of Parkinson’s disease. Brain 16:1727–1751CrossRef
23.
Zurück zum Zitat Costafreda SG, Fu CH, Lee L, Everitt B, Brammer MJ, David AS (2006) A systematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus. Hum Brain Mapp 27(10):799–810CrossRefPubMedPubMedCentral Costafreda SG, Fu CH, Lee L, Everitt B, Brammer MJ, David AS (2006) A systematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus. Hum Brain Mapp 27(10):799–810CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Henry JD, Crawford JR (2004) A meta-analytic review of verbal fluency performance following focal cortical lesions. Neuropsychology 18(2):284–295CrossRefPubMed Henry JD, Crawford JR (2004) A meta-analytic review of verbal fluency performance following focal cortical lesions. Neuropsychology 18(2):284–295CrossRefPubMed
25.
Zurück zum Zitat Rittman T, Ghosh BC, McColgan P et al (2013) The Addenbrooke’s Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 84(5):544–551CrossRefPubMed Rittman T, Ghosh BC, McColgan P et al (2013) The Addenbrooke’s Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 84(5):544–551CrossRefPubMed
26.
Zurück zum Zitat Wang YP, Gorenstein C (2013) Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Rev Bras Psiquiatr 35:416–431CrossRefPubMed Wang YP, Gorenstein C (2013) Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Rev Bras Psiquiatr 35:416–431CrossRefPubMed
27.
Zurück zum Zitat Ječmenica-Lukić M, Pekmezović T, Petrović IN, Tomić A, Svetel M, Kostić VS (2018) Use of the neuropsychiatric inventory to characterize the course of neuropsychiatric symptoms in progressive supranuclear palsy. J Neuropsychiatry Clin Neurosci 30(1):38–44CrossRefPubMed Ječmenica-Lukić M, Pekmezović T, Petrović IN, Tomić A, Svetel M, Kostić VS (2018) Use of the neuropsychiatric inventory to characterize the course of neuropsychiatric symptoms in progressive supranuclear palsy. J Neuropsychiatry Clin Neurosci 30(1):38–44CrossRefPubMed
28.
Zurück zum Zitat Almeida L, Ahmed B, Walz R et al (2017) Depressive Symptoms are frequent in atypical parkinsonian disorders. Mov Disord Clin Pract 4(2):191–197CrossRefPubMed Almeida L, Ahmed B, Walz R et al (2017) Depressive Symptoms are frequent in atypical parkinsonian disorders. Mov Disord Clin Pract 4(2):191–197CrossRefPubMed
29.
Zurück zum Zitat Wilson RS, Nag S, Boyle PA et al (2013) Brainstem aminergic nuclei and late-life depressive symptoms. JAMA Psychiatry 70:1320–1328CrossRefPubMed Wilson RS, Nag S, Boyle PA et al (2013) Brainstem aminergic nuclei and late-life depressive symptoms. JAMA Psychiatry 70:1320–1328CrossRefPubMed
30.
Zurück zum Zitat Benoit M, Robert PH (2011) Imaging correlates of apathy and depression in Parkinson’s disease. J Neurol Sci 310:58–60CrossRefPubMed Benoit M, Robert PH (2011) Imaging correlates of apathy and depression in Parkinson’s disease. J Neurol Sci 310:58–60CrossRefPubMed
31.
Zurück zum Zitat Jellinger KA (2008) Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Neurodegener Dis 5(6):339–346CrossRefPubMed Jellinger KA (2008) Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Neurodegener Dis 5(6):339–346CrossRefPubMed
Metadaten
Titel
Motor, cognitive and behavioral differences in MDS PSP phenotypes
verfasst von
Marina Picillo
Sofia Cuoco
Maria Francesca Tepedino
Arianna Cappiello
Giampiero Volpe
Roberto Erro
Gabriella Santangelo
Maria Teresa Pellecchia
Paolo Barone
The PSP Salerno study group
Publikationsdatum
15.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 7/2019
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-019-09324-x

Weitere Artikel der Ausgabe 7/2019

Journal of Neurology 7/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.